The introduction of nicotinamide as a nicotine alternative in e-cigarette and smokeless products and solutions represents a big regulatory problem to the FDA. Nicotinamide doesn't have nicotinic receptor agonist activity and is thought to work as a sedative at substantial dosages6. The promises made by Nicotine River, ECBlend, together with other s